3 Exciting Biotechs Under $30: Flexion Therapeutics' Response to the Opioid Epidemic
The opioid epidemic is a huge and tragic problem, and the market is starved for solutions. Flexion Therapeutics (NASDAQ: FLXN) is one company that's working on filling that gap and is close to potentially releasing its treatment to the market.
In this Industry Focus: Healthcare segment, Motley Fool analyst Kristine Harjes and contributor Todd Campbell explain why so many people are prescribed opioids for pain today, what indication Flexion is targeting with Zilretta, how Flexion's treatment works and when it will be approved or rejected by the Food and Drug Administration, how Zilretta differs from existing treatments in some really exciting ways, and more.
A full transcript follows the video.
Source: Fool.com
